Physician profile
Scott A Hammer
NPI 1679557722
$1,124.05
in general payments reported to CMS, 2019-2025
19 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $39.20 · 2022: $39.17 · 2023: $225 · 2024: $213 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $241.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $178.31 | 2019-2024 | Breztri, Airsupra |
| Abbott Laboratories | $141.82 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $99.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $76.61 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $75.51 | 2020-2025 | |
| Amgen INC. | $45.23 | 2022-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $43.22 | 2019 | |
| Linus Health, INC. | $37.38 | 2023-2024 | Core Cognitive Evaluation |
| Janssen Pharmaceuticals, INC | $26.20 | 2019 | |
| Axsome Therapeutics, INC. | $23.61 | 2024 | Auvelity |
| Irhythm Technologies, INC. | $21.83 | 2024 | Zio Xt Patch, Zio Monitor |
| Dexcom, INC. | $18.66 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $17.90 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $17.50 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $16.91 | 2024 | |
| Sanofi-Aventis U.S. LLC | $16.64 | 2019 | |
| Glaxosmithkline, LLC. | $13.57 | 2019 | |
| Bardy Diagnostics, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.